<DOC>
	<DOCNO>NCT01540344</DOCNO>
	<brief_summary>The COMBATAC study evaluate effect assess progression-free survival ( PFS ) perioperative systemic chemotherapy include cetuximab cytoreductive surgery ( CRS ) bidirectional hyperthermic intraperitoneal chemotherapy ( HIPEC ) patient peritoneal carcinomatosis arise colorectal cancer .</brief_summary>
	<brief_title>Combined Anticancer Treatment Advanced Colon Cancer</brief_title>
	<detailed_description>More 10 % patient colorectal cancer ( CRC ) already show peritoneal carcinomatosis time initial diagnosis 25 % patient develop peritoneal carcinomatosis natural course disease common sign tumor progression recurrence . The exist data suggests CRS HIPEC integral part multidisciplinary treatment concept may improve long-term survival select patient peritoneal carcinomatosis colonic origin . Moreover , hyperthermic peritoneal perfusion oxaliplatin combination synchronous application 5-FU/leucovorin seem improve efficacy HIPEC comparison mitomycin C-based intraperitoneal treatment regimen may lead good local tumor control . The improved systemic treatment strategy neoadjuvant chemotherapy may lead increase rate complete macroscopic cytoreduction together adjuvant treatment well control distant metastasis tumor recurrence . However , prospective study available evaluate clinical oncological outcome standard-of-care chemotherapy include targeted anticancer therapy combination CRS HIPEC . The published morbidity mortality rate CRS HIPEC comparable major gastrointestinal surgery seem acceptable consider expected improvement oncological outcome .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Synchronous metachronous peritoneal carcinomatosis arise histologically prove colorectal appendiceal adenocarcinoma Complete macroscopic cytoreduction ( CCR0/1 ) Free treatment interval least 6 month last chemotherapy Age 18 71 year Good general health status ( Karnofsky &gt; 70 % , ECOG 02 ) Absence hematogenous metastasis ( lung , bone , brain , &gt; 3 peripheric resectable liver metastasis ) Absence contraindication systemic chemotherapy and/or extend surgery Life expectancy great 6 month Written inform consent Creatinine clearance &gt; 50 ml/min , serum creatinine ≤ 1.5 x ULN Serum bilirubin ≤ 1.5 x ULN ( upper limit normal ) , ASAT ALAT ≤ 2.5 x ULN Platelet count &gt; 100,000 /ml , haemoglobin &gt; 9 g/dl , neutrophile granulocyte ≥ 1,500 /ml , International Normalized Ration ( INR ) ≤ 2 Absence peripheral neuropathy &gt; grade 1 ( CTCAE v4.0 ) No pregnancy breast feeding . Adequate contraception fertile patient . Incomplete cytoreduction Hematogenous metastasis include irresectable liver metastasis Prior chemotherapy therapy EGFR receptor antibody metastatic disease Kras mutation Known allergy murine chimeric monoclonal antibody Histology signet ring carcinoma Other malignancy disease study / second cancer Impaired liver , renal hematologic function mention ( inclusion criterion ) Heart failure NYHA ≥ 2 significant Coronary Artery Disease Alcohol and/or drug abuse Patients unable unwilling comply study protocol , treatment followup Patients include clinical trial interfere present study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>peritoneal carcinomatosis</keyword>
	<keyword>cytoreductive surgery</keyword>
	<keyword>HIPEC</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>